Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
378.92
-35.38 (-8.54%)
At close: Nov 2, 2026, 4:00 PM EST
385.32
+6.40 (1.69%)
Pre-market: Nov 3, 2026, 7:35 AM EST
Natera Revenue
Natera had revenue of $752.75M in the quarter ending June 30, 2026, with 37.71% growth. This brings the company's total for the last twelve months to $2.71B, up 37.82% year-over-year. In the year 2025, Natera had annual revenue of $2.31B with 35.90% growth. That makes Natera the 4,096th largest company in the world by revenue and 1,116th in the United States.
Revenue (ttm)
$2.71B
Revenue Growth
+37.82%
P/S Ratio
20.18
Revenue / Employee
$440,892
Employees
6,140
Market Cap
54.62B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Natera breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.31B | 609.20M | 35.90% |
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Danaher | 25.61B |
| IQVIA Holdings | 17.31B |
| Labcorp Holdings | 14.59B |
| Quest Diagnostics | 11.84B |
| Agilent Technologies | 7.37B |
| IDEXX Laboratories | 4.66B |
| Waters | 4.64B |
| Illumina | 4.54B |
NTRA News
- 11 minutes ago - Natera announces its Signatera MRD test received Medicare coverage - TheFly
- 5 days ago - Natera to Report its Third Quarter Results on November 5, 2026 - Business Wire
- 7 days ago - Natera highlights Signatera Genome Assay at ESMO Congress - TheFly
- 7 days ago - Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer - Business Wire
- 7 days ago - Natera price target raised to $430 from $320 at BTIG - TheFly
- 8 days ago - Natera announces new data presented at ASN Kidney Week 2026 - TheFly
- 8 days ago - Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™ - Business Wire
- 11 days ago - Natera initiated with a Buy at Roth Capital - TheFly